Literature DB >> 3344528

Evidence for an enterohepatic circulation of ochratoxin A in mice.

A Roth1, K Chakor, E E Creppy, A Kane, R Roschenthaler, G Dirheimer.   

Abstract

The distribution and elimination of [3H]ochratoxin A (OTA) from stomach content and tissue, intestine content and tissue, liver, bile, serum and urine of Swiss male mice which had received a single low dose of OTA by intubation was followed as a function of time. The profiles of radioactivity do not show a smooth decline after the absorption period, but an oscillating pattern with rapid declines followed by increases which favour the assumption of an enterohepatic circulation. Between 28% and 68% of conjugated OTA together with OTA cleavage products were found in bile giving evidence for biliary excretion of OTA and its metabolites in mice. When given i.m. to mice [3H]OTA is already found after 30 min in bile and intestine contents and its elimination patterns show several peaks confirming the biliary excretion and the enterohepatic circulation. Cholestyramine, which is known to prevent the enterohepatic circulation of drugs and toxins, changes the profile of elimination of OTA which no longer presents the cyclic pattern. This result is also in favour of an enterohepatic circulation of OTA. When phenylalanine is given together with OTA by oral gavage the toxicokinetics of the mycotoxin change completely in the different body fluids, in stomach and intestine content and tissues. Phenylalanine seems to facilitate the gastric absorption of OTA and the gastro-intestinal transit. It increases also its early excretion into urine and bile. However, its elimination pattern no longer shows the oscillating pattern. Thus phenylalanine seems to inhibit the intestinal reabsorption of OTA conjugates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3344528     DOI: 10.1016/0300-483x(88)90110-2

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  15 in total

1.  Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice.

Authors:  K L Underhill; B A Rotter; B K Thompson; D B Prelusky; H L Trenholm
Journal:  Bull Environ Contam Toxicol       Date:  1995-01       Impact factor: 2.151

2.  Evidence of ochratoxin A conjugates in urine samples from infants and adults.

Authors:  K Muñoz; B Cramer; J Dopstadt; H-U Humpf; G H Degen
Journal:  Mycotoxin Res       Date:  2016-11-09       Impact factor: 3.833

Review 3.  New Evidences about the Carcinogenic Effects of Ochratoxin A and Possible Prevention by Target Feed Additives.

Authors:  Stoycho D Stoev
Journal:  Toxins (Basel)       Date:  2022-05-30       Impact factor: 5.075

Review 4.  Ochratoxin A and human health risk: a review of the evidence.

Authors:  Travis R Bui-Klimke; Felicia Wu
Journal:  Crit Rev Food Sci Nutr       Date:  2015       Impact factor: 11.176

5.  Hydrolysis of ochratoxin A by the microbial activity of digesta in the gastrointestinal tract of rats.

Authors:  M S Madhyastha; R R Marquardt; A A Frohlich
Journal:  Arch Environ Contam Toxicol       Date:  1992-11       Impact factor: 2.804

Review 6.  Ochratoxins in feed, a risk for animal and human health: control strategies.

Authors:  Muzaffer Denli; Jose F Perez
Journal:  Toxins (Basel)       Date:  2010-05-13       Impact factor: 4.546

7.  Studies on carcinogenic and toxic effects of ochratoxin A in chicks.

Authors:  Stoycho D Stoev
Journal:  Toxins (Basel)       Date:  2010-04-12       Impact factor: 4.546

8.  Pharmacokinetics of CamSA, a potential prophylactic compound against Clostridioides difficile infections.

Authors:  Christopher Yip; Naomi C Okada; Amber Howerton; Amei Amei; Ernesto Abel-Santos
Journal:  Biochem Pharmacol       Date:  2020-11-03       Impact factor: 5.858

Review 9.  A review of the mechanism of injury and treatment approaches for illness resulting from exposure to water-damaged buildings, mold, and mycotoxins.

Authors:  Janette Hope
Journal:  ScientificWorldJournal       Date:  2013-04-18

10.  Complex etiology, prophylaxis and hygiene control in mycotoxic nephropathies in farm animals and humans.

Authors:  Stoycho D Stoev
Journal:  Int J Mol Sci       Date:  2008-04-18       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.